Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

trastuzumab deruxtecan 1trametinib 1spartalizumab 1ribociclib 1pexidartinib 1pembrolizumab 1dabrafenib 1Thalidomide 1Sunitinib 1Specimen Handling 1OSI 930 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Cisplatin 1Cetuximab 1Capecitabine 1CTLA-4 Antigen 17-hydroxystaurosporine 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × OSI 930 × Head & Neck × Clear all
NCT00513851 2011-09-27

Phase 1 Study of OSI-930 in Cancer Patients

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡